John Crawford
Neurology with Special Qualifications in Child Neurology · San Diego, CANPI 1982790259
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,751 of the $26,755 with a category attached, or 92.5%. Merck accounts for 72.9% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2020 at $15,385 and has fallen 99.2% since, to $119 in 2025. Among neurology with special qualifications in child neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 90 payments — averaging $297.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$20K
- AstraZeneca$5K
- Sunovion Pharmaceuticals Inc.$640
- SK Life Science, Inc.$249
- Monteris Medical Corporation$200
- Mallinckrodt Enterprises LLC$187
- plus $742 from 17 others
Across 1 payment — averaging $2800.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$3K
What the payments were for
- Consulting fees$24,75193%
- Food & beverage$2,0047%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 4 | $19,500 |
| AstraZeneca(2 entities) | 6 | $5,237 |
| Sunovion Pharmaceuticals Inc. | 43 | $640 |
| SK Life Science, Inc. | 2 | $249 |
| Monteris Medical Corporation | 1 | $200 |
| Mallinckrodt Enterprises LLC | 8 | $187 |
| Neurelis, Inc. | 2 | $153 |
| UCB, Inc. | 2 | $123 |
| Greenwich Biosciences, Inc. | 3 | $70 |
| Mallinckrodt Hospital Products Inc. | 3 | $63 |
| Aquestive Therapeutics, Inc. | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 2 | $42 |
| Cranial Technologies, Inc | 2 | $29 |
| Springworks Therapeutics, Inc. | 1 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Eisai Inc. | 1 | $24 |
| Zogenix Inc. | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $22 |
| Pfizer | 1 | $21 |
| Upsher-smith Laboratories LLC | 1 | $19 |
| Biomarin Pharmaceutical Inc. | 1 | $18 |
| Novartis | 1 | $18 |
| CSL Behring | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$19,500
- KOSELUGO$3,611
- Neuroblate$200
- VALTOCO$135
How this compares
$26,755 in reported general payments places this provider in the 90th percentile of 216 neurology with special qualifications in child neurology providers in California.
See all neurology with special qualifications in child neurology providers in California →
Other neurology with special qualifications in child neurology in San Diego
- Brittany PassiakSan Diego$90K
- Joseph GleesonSan Diego$69K
- Richard HaasSan Diego$27K
- Shifteh SattarSan Diego$21K
- Jennifer YangSan Diego$15K
- Doris TraunerSan Diego$15K
- Olivia Kim McManusSan Diego$11K
- Katherine LongardnerSan Diego$11K
- Aliya FrederickSan Diego$7K
- Michael ChezSacramento$374K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.